SCHEMBL18006394

SCHEMBL18006394

Cc1noc(C)c1COc1cccc(-c2nn[nH]c2C#N)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.50
ALOX15 P16050 2/20 0.50
HSD17B10 Q99714 1/20 0.50
LMNA P02545 5/20 0.46
HPGD P15428 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
MAPT P10636 2/20 0.46
TSHR P16473 6/20 0.45
ATM Q13315 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
BRD4 O60885 1/20 0.44
BRD2 P25440 1/20 0.44
CREBBP Q92793 1/20 0.44
KDM4E B2RXH2 2/20 0.44
POLB P06746 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KMT2A Q03164 3/20 0.43
PKM P14618 1/20 0.43
MEN1 O00255 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18006436 0.89 ALOX15 (0.40) ALDH1A1ALOX15HSD17B10LMNAHPGD
SCHEMBL18006399 0.82 CYP11B1 (0.40) ALDH1A1ALOX15HSD17B10HPGDTSHR
SCHEMBL18004234 0.80 PIK3CD (0.47) SMN1; SMN2MAPTKMT2AMEN1
SCHEMBL18004480 0.80 MEN1 (0.41) ALDH1A1MAPTKDM4EKMT2AMEN1
SCHEMBL18006419 0.79 KDR (0.43) HPGDMAPTTSHRPOLBL3MBTL1
SCHEMBL18006437 0.78 CHEK1 (0.39) ALDH1A1HSD17B10HPGDMAPTTSHR
SCHEMBL18005947 0.78 NAAA (0.47) ALOX15LMNAHPGDSMN1; SMN2TSHR
SCHEMBL18006400 0.77 SLC22A12 (0.36) ALDH1A1HPGDMAPTKDM4E
SCHEMBL18006370 0.77 KDR (0.58) MAPTPOLB
SCHEMBL18006441 0.77 CYP11B1 (0.42) ALDH1A1MAPTKDM4EPOLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 ALDH1A1 1611/4885ALOX15 2623/4885HSD17B10 121/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 ALDH1A1 1611/4885ALOX15 2623/4885HSD17B10 121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.